MAFM
VRTX icon

Mid Atlantic Financial Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mid Atlantic Financial Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$235K Sell
1,298
-110
-8% -$21.5K 0.02% 761
2021
Q2 		$284K Sell
1,408
-2
-0.1% -$418 0.02% 690
2021
Q1 		$303K Buy
+1,410
New +$310K 0.02% 625

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mid Atlantic Financial Management's VRTX Position: Q3 2021 in Review

Mid Atlantic Financial Management reduced its Vertex Pharmaceuticals (VRTX) stake by 7.8% in Q3 2021, selling an estimated $21.5K and leaving 1,298 shares worth $235K. The position accounts for 0.02% of the portfolio, ranked #761.

Mid Atlantic Financial Management first reported a position in VRTX in Q1 2021 and has held it in 3 quarters since. The position peaked at $303K in Q1 2021. 934 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Mid Atlantic Financial Management held 1,298 shares of Vertex Pharmaceuticals worth $235K as of Q3 2021.
  • Mid Atlantic Financial Management sold 110 Vertex Pharmaceuticals shares in Q3 2021, an estimated $21.5K.
  • Vertex Pharmaceuticals made up 0.02% of Mid Atlantic Financial Management's portfolio in Q3 2021, its #761 holding.
  • Mid Atlantic Financial Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 3 quarters since.
  • Mid Atlantic Financial Management's Vertex Pharmaceuticals position peaked at $303K in Q1 2021.
  • 934 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Mid Atlantic Financial Management's 13F filing for Q3 2021, filed 12 Nov 2021.